 | | Vol. 12.18 – 18 May, 2021 |
| |
|
|
| Scientists treated 50 patients with severe combined immunodeficiency due to adenosine deaminase (ADA) with an investigational gene therapy composed of autologous CD34+ hematopoietic stem and progenitor cells transduced ex vivo with a self-inactivating lentiviral vector encoding human ADA.
[New England Journal of Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers reconstructed a phylogenetic tree of blood development using whole-genome sequencing of 511 single-cell-derived hematopoietic colonies from healthy human fetuses at 8 and 18 weeks after conception, coupled with deep targeted sequencing of tissues of known embryonic origin.
[Nature] |
|
|
|
| Investigators generated an EVI1-GFP AML model and applied an unbiased CRISPR/Cas9 enhancer scan to uncover sequence motifs essential for EVI1 transcription.
[Cancer Discovery] |
|
|
|
| By combining fluorescent biosensors with time-lapse imaging and microfluidics, researchers measured the activity of the extracellular signal-regulated kinase pathway over time in live single human umbilical cord blood HSCs and multipotent progenitor cells.
[Blood] |
|
|
|
| The authors engineered red blood cells into artificial antigen-presenting cells presenting a peptide bound to the major histocompatibility complex I, the costimulatory ligand 4-1BBL, and interleukin-12.
[Nature Communications] |
|
|
|
| Using a multiomics platform and biochemical and molecular studies, scientists showed that in proliferative chronic myelomonocytic leukemia RAS pathway mutations were associated with a unique gene expression profile enriched in mitotic kinases such as polo-like kinase 1.
[Nature Communications] |
|
|
|
| Researchers used multi-omics and computational tools to analyze multiple bone marrow environmental compartments and deciphered their mutual interactions in the context of acute myeloid leukemia xenografts.
[Cell Reports] |
|
|
|
| Scientists suggested that the dual inhibition of HDAC and HSP90 could suppress the expression of oncogenic pathways in acute leukemia, and MPT0G449 represented a novel therapeutic for anticancer treatment.
[Oncogenesis] |
|
|
|
| Investigators showed that while AMD11070 acts as a full antagonist, plerixafor acts biased by stimulating β-arrestin recruitment while fully antagonizing G protein.
[Communications Biology] |
| |
|
|
| The ENESTop study evaluated treatment-free remission in patients with chronic myeloid leukemia in chronic phase who had received more than three years of tyrosine kinase inhibitor therapy and achieved sustained deep molecular response only after switching from imatinib to nilotinib.
[Leukemia] |
|
|
|
| Investigators initiated a Phase II trial for previously untreated patients with CLL with mutated IGHV and absence of del(17p)/TP53 mutation. Patients received iFCG for three cycles.
[Leukemia] |
|
|
|
|
| Scientists discuss the current state of precision medicine for AML, including both the potential to improve patient outcomes and the related challenges.
[Nature Reviews Clinical Oncology] |
|
|
|
| The authors synthesize what is currently known about how inherited variation shapes the risk of clonal hematopoiesis and how this genetic architecture intersects with the biology of diseases that occur with aging.
[Nature Reviews Genetics] |
|
|
|
|
| Incyte and MorphoSys AG announced that the first patient has been dosed in the pivotal Phase III frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone compared to R-CHOP alone as first-line treatment for high-intermediate and high-risk patients with untreated diffuse large B-cell lymphoma.
[Incyte, Inc. (BusinessWire, Inc)] |
|
|
|
| GT Biopharma, Inc. provided an update concerning the commencement of the GTB-3550 TriKEâ„¢ monotherapy Phase II clinical trial, and certain of its solid tumor targeting TriKEâ„¢ product candidates.
[GT Biopharma, Inc.] |
|
|
|
|
| June 14 – 18, 2021
Virtual |
|
|
|
|
|
| University of California – Davis, California, United States |
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | Astellas Pharma – Westborough, Massachusetts, United States |
|
|
|
| | Technische Universität Dresden – Dresden, Germany |
|
|
|
| | Zhejiang University – Zhejiang, China |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
